Arformoterol

Drug Profile

Arformoterol

Alternative Names: (R,R)-eformoterol; (R,R)-formoterol; Arformoterol tartrate; Arformoterol tartrate inhalation; Brovana; Eformoterol - Sunovion; Formoterol - Sunovion; R,R-eformoterol; R,R-formoterol

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sepracor
  • Developer Sunovion Pharmaceuticals
  • Class Antiasthmatics; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Nov 2014 Discontinued - Phase-II for Asthma (In children) in USA (Inhalation)
  • 08 Jul 2014 Final efficacy and adverse events data from a phase III trial in Chronic obstructive pulmonary disease released by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top